How much does Hammersmith Medicines Research Limited make?

Hammersmith Medicines Research Limited reported revenue of £24.7m and a loss of £1.1m in the year to 31 Jul 2025, according to its accounts filed at Companies House.

How many employees does Hammersmith Medicines Research Limited have?

Hammersmith Medicines Research Limited reported an average of 285 employees in the year to 31 Jul 2025.

Is Hammersmith Medicines Research Limited profitable?

No — Hammersmith Medicines Research Limited reported a loss of £1.1m in the year to 31 Jul 2025.

Company No. 02779946 · Incorporated 15 Jan 1993

Hammersmith Medicines Research Limited

Registered name: HAMMERSMITH MEDICINES RESEARCH LIMITED

Part of Nn Bidco Pty Ltd (Acn 623 536 247) group

Hammersmith Medicines Research Limited made £24.7m revenue and a £1.1m loss in the year to 31 Jul 2025.

Hammersmith Medicines Research Limited’s revenue was £24.7m in the year to 31 Jul 2025, with a loss of £1.1m and 285 employees. The company is classified under “other research and experimental development on natural sciences and engineering” and is based in London; we hold 4 years of its filed accounts.

Full P&L filedSection M · Professional, scientific and technical activitiesSIC 72190Other research and experimental development on natural sciences and engineering

Status: Active
Location: London, London
Age: 33 yrs · since 1993
Type: Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.

Latest accounts · year to 31 Jul 2025

Key figures

Cash flow filed

Revenue

£24.7m

Growth —

Profit

−£1.1m

Growth —

Profit margin

−4.4%

Gross 34.2%

Employees

285

Change —

Profit / employee

−£3.8k

Revenue/employee £86.6k

Profitable streak

0yrs

Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

4 filed years

Financial history

Multi-year financials, oldest to newest
Year to	31 Jan 2022	31 Jan 2023	31 Jan 2024	31 Jul 2025
Disclosure	Full P&Lread from filing text	Full P&Lread from filing text	Full P&L	Full P&L
Profit & loss
Revenue (turnover)	£21.9m	£20.6m	£18.4m	£24.7m
Cost of sales	£14.8m	£14.8m	£11.2m	£16.2m
Gross profit	£7.1m	£5.8m	£7.2m	£8.4m
Operating profit	£1.3m	−£2m	−£7.5m	−£2.3m
Profit before tax	£1.4m	−£2.1m	−£7.4m	−£2.1m
Profit after tax	£530k	−£1.4m	−£729k	−£1.1m
Profit (best available)	£530k	−£1.4m	−£729k	−£1.1m
Staff costs	—	—	£12.5m	£20.1m
Employees (average)	291	308	291	285
Ratios
Profit margin	2.4%	−6.8%	−4%	−4.4%
Gross margin	32.5%	28%	39%	34.2%
Revenue per employee	£75.3k	£66.9k	£63.1k	£86.6k
Profit per employee	£1.8k	−£4.5k	−£2.5k	−£3.8k
Growth (year on year)
Revenue growth	—	▼6%	▼11%	—
Profit growth	—	▼363.4%	—	—
Headcount growth	—	▲5.8%	▼5.5%	—
Balance sheet — indirect signals, not revenue
Cash at bank	£4.8m	£1.9m	£3.7m	£2.3m
Net assets	£25.7m	£24.4m	£23.7m	£16.2m
Fixed assets	£11.9m	£11.6m	£11.3m	£4.8m
Current assets	£18.1m	£17.2m	£17m	£14.5m
Debtors	£4m	£3.8m	£2.9m	£1.3m
Deferred income	—	—	£1.3m	£1.5m
Cash from operations	—	—	£2.9m	−£2.5m
Source	FullAccounts · bulk data Apr 2024	FullAccounts · bulk data Apr 2024	FullAccounts · bulk data May 2025	FullAccounts · bulk data Jun 2026

Derived from the latest filing

How the business works

Profit margin: −4.4%; Profit ÷ revenue.
Gross margin: 34.2%; Gross profit ÷ revenue. High for software and services.
Revenue per employee: £86.6k; Revenue ÷ average employees.
Profit per employee: −£3.8k; Profit ÷ average employees.
Cash conversion: —; Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue: 19.4%; Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue: 5.9%; Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue: 5.4%; Money owed by customers. Low = customers pay quickly.

Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets: —; Now £16.2m
Cash at bank: —; Now £2.3m
Headcount: —; Now 285
Deferred income: —; Now £1.5m
Fixed assets: —; Now £4.8m

Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.

Corporate ownership

Group structure

Ownership chain

Nn Bidco Pty Ltd (Acn 623 536 247) (registered outside the UK register)ultimate parent75–100%
Hammersmith Medicines Research Limitedthis company

Bands show the share of ownership each company holds in the one below it.

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Companies House profile Filing history & original accounts

Latest figures from FullAccounts for the year to 31 Jul 2025 (profit −£1.1m), from the Companies House accounts bulk data published Jun 2026. Spotted an error? Request a correction.

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.